Due to the late application of HER-2-targeting therapy compared with traditional chemotherapy drugs, breast cancer patients were treated with HER-2-targeting drugs later than conventional chemotherapy drugs, such as anthracyclines. Here, ERBB2 is linked to breast cancer.